Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 17 November 2014 | By Louise Zornoza,
This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.
The Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have provided funding for a Phase I clinical trial using Canada’s Ebola vaccine (VSV-EBOV), Canada's Minister of Health, Rona Ambrose, announced last week.
The Canadian Immunization Research Network (CIRN) is conducting the trial, which will take place in Nova Scotia, with 40 volunteers between the ages of 18-65. The trial is taking place concurrently with trials on the same vaccine in the United States in order to expedite the move to clinical trials in larger populations.
The CIRN was created in 2014 to enhance Canada’s ability to rapidly test new vaccines and foster the exchange of information among vaccine researchers and government decision makers.
(Canadian Center for Vaccinology)
Tags: RegLink, CIRN, Ebola, Vaccine, Ebola Vaccine, Canadian Institutes of Health Research, Public Health Agency of Canada